297 related articles for article (PubMed ID: 22043054)
1. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
Curigliano G; Goldhirsch A
J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
[TBL] [Abstract][Full Text] [Related]
2. Novel treatment approaches for triple-negative breast cancer.
Telli ML; Ford JM
Clin Breast Cancer; 2010; 10 Suppl 1():E16-22. PubMed ID: 20587403
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of triple-negative breast cancer.
de Ruijter TC; Veeck J; de Hoon JP; van Engeland M; Tjan-Heijnen VC
J Cancer Res Clin Oncol; 2011 Feb; 137(2):183-92. PubMed ID: 21069385
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic options for triple-negative breast cancers with defective homologous recombination.
Jaspers JE; Rottenberg S; Jonkers J
Biochim Biophys Acta; 2009 Dec; 1796(2):266-80. PubMed ID: 19616605
[TBL] [Abstract][Full Text] [Related]
6. [Novel target therapies used in breast cancer management].
Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
[No Abstract] [Full Text] [Related]
7. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Silver DP; Richardson AL; Eklund AC; Wang ZC; Szallasi Z; Li Q; Juul N; Leong CO; Calogrias D; Buraimoh A; Fatima A; Gelman RS; Ryan PD; Tung NM; De Nicolo A; Ganesan S; Miron A; Colin C; Sgroi DC; Ellisen LW; Winer EP; Garber JE
J Clin Oncol; 2010 Mar; 28(7):1145-53. PubMed ID: 20100965
[TBL] [Abstract][Full Text] [Related]
8. Management of triple negative breast cancer.
Oakman C; Viale G; Di Leo A
Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
[TBL] [Abstract][Full Text] [Related]
9. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R
Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
11. Dissecting the heterogeneity of triple-negative breast cancer.
Metzger-Filho O; Tutt A; de Azambuja E; Saini KS; Viale G; Loi S; Bradbury I; Bliss JM; Azim HA; Ellis P; Di Leo A; Baselga J; Sotiriou C; Piccart-Gebhart M
J Clin Oncol; 2012 May; 30(15):1879-87. PubMed ID: 22454417
[TBL] [Abstract][Full Text] [Related]
12. Systemic Therapies for Nonmetastatic Breast Cancer: The Role of Neoadjuvant and Adjuvant Chemotherapy and the Use of Endocrine Therapy.
Bychkovsky BL; Dizon DS; Sikov WM
Clin Obstet Gynecol; 2016 Dec; 59(4):756-771. PubMed ID: 27741213
[TBL] [Abstract][Full Text] [Related]
13. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
14. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative breast cancer: disease entity or title of convenience?
Carey L; Winer E; Viale G; Cameron D; Gianni L
Nat Rev Clin Oncol; 2010 Dec; 7(12):683-92. PubMed ID: 20877296
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.
Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R
Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793
[TBL] [Abstract][Full Text] [Related]
17. Triple-negative breast cancer.
Bartsch R; Ziebermayr R; Zielinski CC; Steger GG
Wien Med Wochenschr; 2010 Apr; 160(7-8):174-81. PubMed ID: 20473728
[TBL] [Abstract][Full Text] [Related]
18. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?
Berrada N; Delaloge S; André F
Ann Oncol; 2010 Oct; 21 Suppl 7():vii30-5. PubMed ID: 20943632
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy options in BRCA mutation-associated breast cancer.
Bayraktar S; Glück S
Breast Cancer Res Treat; 2012 Sep; 135(2):355-66. PubMed ID: 22791366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]